Alcoholic Hepatitis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes

DelveInsight's "Alcoholic Hepatitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alcoholic Hepatitis, historical and forecasted epidemiology as well as the Alcoholic Hepatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Alcoholic Hepatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alcoholic Hepatitis Market Forecast
https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Alcoholic Hepatitis Market Report:
• The Alcoholic Hepatitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, Surrozen discontinued its only clinical asset following a Phase I failure and is now exploring a shift toward ophthalmology. The company has decided to halt the development of SZN-043 for severe alcohol-associated hepatitis. The therapy was being tested in two Phase I trials: one (ACTRN12624000194561) assessing its safety, tolerability, and pharmacokinetics (PK) in patients with severe alcohol-associated hepatitis, and another (ACTRN12622000392763) evaluating its safety and PK through a single and multiple ascending dose study in healthy volunteers and individuals with liver cirrhosis.
• The Alcoholic Hepatitis market is projected to experience consistent growth, with a compound annual growth rate (CAGR) of 6% between 2024 and 2034. This growth across the 7MM is fueled by the launch of advanced therapies like Larsucosterol and INT-787, as well as an increasing prevalence of the condition driven by genetic predispositions and lifestyle factors, particularly alcohol use.
• DelveInsight's epidemiology model estimates that there were around 250,000 diagnosed prevalent cases of alcoholic hepatitis in the US in 2023. This figure is expected to grow over the forecast period (2024-2034), driven by enhanced awareness, improved screening practices, and progress in genetic testing.
• Within the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent alcoholic hepatitis cases, totaling about 174,000 in 2023, while Spain reported the lowest, with approximately 109,000 cases.
• In the United States in 2023, gender-specific diagnosed prevalent cases of alcoholic hepatitis included approximately 188,000 males and around 63,000 females.
• In Japan, alcoholic hepatitis cases were categorized by severity into mild and moderate to severe in 2023. Moderate to severe cases were more prevalent, with approximately 94,000 cases compared to 63,000 mild cases.
• Key Alcoholic Hepatitis Companies: Durect Corporation, Novartis, Intercept Pharmaceuticals, Immuron Ltd., Gilead Sciences, Hoffmann-La Roche, Cellaion SA, and others
• Key Alcoholic Hepatitis Therapies: DUR-928, Canakinumab, INT-787, IMM 124-E, Selonsertib, Orlistat (Xenical), HepaStem, and others
• The Alcoholic Hepatitis epidemiology based on gender analyzed that there are more cases for Alcoholic Hepatitis in males than females
• The Alcoholic Hepatitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alcoholic Hepatitis pipeline products will significantly revolutionize the Alcoholic Hepatitis market dynamics.

Alcoholic Hepatitis Overview
Alcoholic Hepatitis is a severe inflammatory condition of the liver caused by excessive alcohol consumption over time. It occurs when prolonged alcohol abuse damages liver cells, leading to inflammation and impaired liver function. Symptoms include jaundice, abdominal pain, fever, and nausea. In severe cases, it can result in liver failure. Treatment involves alcohol cessation, nutritional support, and in some cases, medications like corticosteroids or liver transplantation. Early intervention can improve outcomes, but continued alcohol use can lead to further liver damage or cirrhosis.

Get a Free sample for the Alcoholic Hepatitis Market Report:
https://www.delveinsight.com/report-store/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alcoholic Hepatitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alcoholic Hepatitis Epidemiology Segmentation:
The Alcoholic Hepatitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Alcoholic Hepatitis
• Prevalent Cases of Alcoholic Hepatitis by severity
• Gender-specific Prevalence of Alcoholic Hepatitis
• Diagnosed Cases of Episodic and Chronic Alcoholic Hepatitis

Download the report to understand which factors are driving Alcoholic Hepatitis epidemiology trends @ Alcoholic Hepatitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alcoholic Hepatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alcoholic Hepatitis market or expected to get launched during the study period. The analysis covers Alcoholic Hepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alcoholic Hepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alcoholic Hepatitis Therapies and Key Companies
• Larsucosterol: Durect Corporation
• DUR-928: Durect Corporation
• INT-787: Intercept Pharmaceuticals
• IMM 124-E: Immuron Ltd.
• Canakinumab: Novartis
• Selonsertib: Gilead Sciences
• Orlistat (Xenical): Hoffmann-La Roche
• HepaStem: Cellaion SA

Discover more about therapies set to grab major Alcoholic Hepatitis market share @ Alcoholic Hepatitis Treatment Market
https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Alcoholic Hepatitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Alcoholic Hepatitis Companies: Durect Corporation, Novartis, Intercept Pharmaceuticals, Immuron Ltd., Gilead Sciences, Hoffmann-La Roche, Cellaion SA, and others
• Key Alcoholic Hepatitis Therapies: DUR-928, Canakinumab, INT-787, IMM 124-E, Selonsertib, Orlistat (Xenical), HepaStem, and others
• Alcoholic Hepatitis Therapeutic Assessment: Alcoholic Hepatitis current marketed and Alcoholic Hepatitis emerging therapies
• Alcoholic Hepatitis Market Dynamics: Alcoholic Hepatitis market drivers and Alcoholic Hepatitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Alcoholic Hepatitis Unmet Needs, KOL's views, Analyst's views, Alcoholic Hepatitis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.